http://www.biotica.com/index.php/biotica/news_article The latest news from Biotica Technology Ltd en Copyright 2013 2013-01-09T09:11:33+00:00 http://www.biotica.com/index.php/biotica/news_article/drug_discovery_company_biotica_technology_limited_placed_into_administratio/ http://www.biotica.com/index.php/biotica/news_article/drug_discovery_company_biotica_technology_limited_placed_into_administratio/#When:09:11:33Z Drug discovery company Biotica Technology Limited, which specialises in novel polyketide therapeutics to create new medicines for serious diseases, appointed Chris McKay and Andrew McTear joint administrators… 2013-01-09T09:11:33+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_and_delos_partner_to_develop_polyketide_therapeutics_in_aging-relat/ http://www.biotica.com/index.php/biotica/news_article/biotica_and_delos_partner_to_develop_polyketide_therapeutics_in_aging-relat/#When:08:51:29Z CAMBRIDGE, October 25, 2012. Biotica announces that it has granted an exclusive license to its rapamycin analogue program to Delos Pharmaceuticals, Inc. (Novato, CA).  The program includes drug… 2012-10-25T08:51:29+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_to_present_at_the_easl_international_liver_congress_2012_in_barcelo/ http://www.biotica.com/index.php/biotica/news_article/biotica_to_present_at_the_easl_international_liver_congress_2012_in_barcelo/#When:08:57:38Z Biotica, the leader in discovery of polyketide therapeutics, will present data on its cyclophilin inhibitor drug candidate, BC556, at the EASL International Liver Congress in Barcelona on the 20th… 2012-04-03T08:57:38+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_moves_to_new_business_premises_on_granta_park_cambridge/ http://www.biotica.com/index.php/biotica/news_article/biotica_moves_to_new_business_premises_on_granta_park_cambridge/#When:10:13:29Z Biotica Technology Ltd, the leader in discovery and development of polyketide therapeutics, announces its relocation to custom-built laboratory and office space on Granta Park near Cambridge. The state-of-the-art… 2012-01-03T10:13:29+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_nominates_drug_candidate_bc556_a_cyclophilin_inhibitor_to_treat_hep/ http://www.biotica.com/index.php/biotica/news_article/biotica_nominates_drug_candidate_bc556_a_cyclophilin_inhibitor_to_treat_hep/#When:09:53:59Z Biotica Technology Limited (Biotica), a privately-held biotechnology company that discovers and develops polyketide therapeutics, today announces the nomination of its drug candidate, BC556, a cyclophilin… 2011-10-31T09:53:59+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_announces_the_sangamides/ http://www.biotica.com/index.php/biotica/news_article/biotica_announces_the_sangamides/#When:08:57:33Z A new class of compounds with potential to provide a key component of combination therapy in Hepatitis C Sangamide class published in Medicinal Chemistry Communications and… 2011-10-24T08:57:33+00:00 http://www.biotica.com/index.php/biotica/news_article/buck_institute_and_biotica_to_investigate_polyketides_in_extension_of_healt/ http://www.biotica.com/index.php/biotica/news_article/buck_institute_and_biotica_to_investigate_polyketides_in_extension_of_healt/#When:13:45:57Z The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging. Building… 2011-09-14T13:45:57+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_regains_worldwide_rights_to_its_rapamycin_analogue_program/ http://www.biotica.com/index.php/biotica/news_article/biotica_regains_worldwide_rights_to_its_rapamycin_analogue_program/#When:08:36:51Z Biotica Technology Ltd. (Cambridge, UK) today announced that it has regained full rights from Pfizer Inc. (NYSE: PFE) to its rapamycin analogue program, including transfer of data and… 2011-08-03T08:36:51+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_to_present_at_the_easl_international_liver_congress_2011_in_berlin/ http://www.biotica.com/index.php/biotica/news_article/biotica_to_present_at_the_easl_international_liver_congress_2011_in_berlin/#When:11:17:02Z Cambridge, UK 9 March 2011 Biotica, the leader in discovery of polyketide therapeutics, today announces that it is presenting data from its nPT-CyP cyclophilin inhibitor programme at the EASL… 2011-03-09T11:17:02+00:00 http://www.biotica.com/index.php/biotica/news_article/biotica_extends_license_to_amyris_for_polyketide_engineering_technology/ http://www.biotica.com/index.php/biotica/news_article/biotica_extends_license_to_amyris_for_polyketide_engineering_technology/#When:12:04:50Z Cambridge, UK: 16 February 2011 Biotica Technology Ltd. announces today that it has signed an agreement with Amyris, Inc. (NASDAQ: AMRS) under which Amyris obtains a non-exclusive license… 2011-02-16T12:04:50+00:00